Protalix Q3 2022 Earnings Report
Key Takeaways
Protalix BioTherapeutics reported its Q3 2022 financial results, highlighted by a significant increase in revenue from selling goods, driven by higher sales to Pfizer and Chiesi, which was partially offset by decreased sales to Brazil. Revenue from licenses and R&D services decreased. The company resubmitted its BLA to the FDA for PRX-102. Net loss decreased compared to the same period in 2021.
Resubmitted BLA to the FDA for PRX-102 for Fabry disease treatment.
Revenue from selling goods increased by 96% to $8.8 million.
Revenue from licenses and R&D services decreased by 28% to $5.4 million.
Net loss for the quarter was $3.6 million, an improvement compared to $4.2 million in the same period last year.
Protalix
Protalix
Forward Guidance
No forward guidance provided in this earnings report.